Значение особенностей действия антиагрегантов для выбора терапии сосудистого больного
УДК 616.155.2:615.035
Ключевые слова:
агрегация тромбоцитов, клопидогрел, тикагрелор, прасугрел
Аннотация
Резюме. В обзорной статье представлены современные данные о клинико-фармакологических особенностях трех современных антиагрегантных препаратов — клопидогрела (плавикс и его генерики), тикагрелора (брилинта) и прасугрела (эффиент). Рассмотрены особенности каждого из препаратов и показания к их назначению в различных клинических ситуациях.
Литература
- Patrono C., Andreotti F., Arnesen H. et al. Antiplatelet agents for
the treatment and prevention of atherothrombosis. Eur Heart J.
2011; 32 (23): 2922–32. - Koln P., Windecker S., Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014; 35: 2541–
619. - Montalescott J., Collet J. P., Ecollan P. et al. Effect of prasugrel pretreatment strategy in patients undergoing percutaneous coronary
intervention for NSTEMI. The ACCOAST-PCI Study. JACC. 2014;
64 (24): 2563–71. - Amsterdam E., Wenger N., Brindis R. et al. 2014 AHA/ACC Guideline for the management of patients with Non-ST-Elevation Acute
Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 64 (24): e139-e228. - Gurbel P., Bliden K., Butler K. et al. Randomized double-blind
assessment of the ONSET and OFFSET of the antiplatelet effects
of ticagrelor versus clopidogrel in patients with stable coronary
artery disease. The ONSET/OFFSET Study. Circulation. 2009; 120:
2577–85. - Puymirat E., Schiele F., Zeller M. et al. Do randomized clinical
trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? The PEGASUS trial in the light of the FAST-MI 2005 registry. Intern J Cardiol. 2016; 223: 604–10. - Wisman P., Roest M., Asselbergs F. et al. Platelet‐reactivity tests
identify patients at risk of secondary cardiovascular events: a systematic review and meta‐analysis. J Thromb Haemost. 2014; 12
(5): 736–47. - Dalal J., Digrajkar A., Gandhi A.Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center. Indian
Heart J. 2016; 68 (5): 624–31. - Bonello L., Pansieri M., Mancini J. et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events
after percutaneous coronary intervention in acute coronary syndromes. JACC. 2011; 58: 467–73. - Mehta S., Tanguay J-F., Eikelboom J. et al. CURRENT-OASIS7
trial investigators. High dose versus standard-dose clopidogrel
and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS7): a randomised factorial trial. Lancet. 2010; 376 (9748): 1233–43. - Aradi D., Tornyos A., Pinter T. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. JACC. 2014; 63 (11): 1061–70.
- Tantry U., Bonello L., Aradi D. For the Working Group on OnTreatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. JACC. 2013; 62 (24):
2261–73. - StuckeyT. D., KirtaneA. J., BrodieB. R. et al. Impact of aspirin and
clopidogrel hyporesponsiveness in patients treated with drug-eluting stents: 2-year results of a prospective, multicenter registry study.
JACC Cardiovasc Interv. 2017; 10 (16) [Epub ahead of print]. DOI:
10.1016/j.jcin.2017.05.059. - Becker R., Bassand J., Budai A. et al. Bleeding complications with
the P2Y12 receptor antagonists clopidogrel and ticagrelor in the
PLATelet inhibition and patient Outcomes (PLATO) Trial. Eur
Heart J. 2011: 32 (23): 2933–44. - Rossini R., Musumeci G., Capodanno D. et al. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of multicentre
registry. Thromb Haemost. 2015; 113 (2): 272–82. - Aradi D., Kirtane A., Bonello L. et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of
platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015; 36 (27): 1762–71. - Jin L., YuH., Dong T. et al. The prognostic value of ADP-induced
platelet aggregation for bleeding complications in low — intermediate risk patients with acute coronary syndrome taking clopidogrel after percutaneous coronary intervention. Heart Lung Circulation. 2017; 26 (1): 49–57. - Mehran R., Baber U., Steg G. et al. Cessation of dual antiplatelet
treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational
study. Lancet. 2013; 382 (9906): 1714–22. - Cruden N., Din J., Janssen C. et al. Delay in filling first clopidogrel
prescription after coronary stenting is associated with an increased
risk of death and myocardial infarction. JAHA. 2014; 3 (3): e000669. - Schoos M., Chandrasekhar J., Baber U. et al. Causes, timing and
impact of dual antiplatelet therapy interruption for surgery (from
the patterns of non-adherense to anti-platelet regimens in stented
patients registry). Am J Cardiol. 2017 [Epub ahead of print]. DOI:
10.1016/j.amjcard.2017.06.016. - Kristensen S., Knuuti J., Saraste A. et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J. 2014; 35 (35): 2383–431.
- Agewall S., Cattaneo M., Collet J. et al. On behalf of ESC Working
Group on Cardiovascular Pharmacology and Drug Therapy and ESC
Working Group on Thrombosis. Eur Heart J. 2013; 34 (23): 1708–13. - Sousa-Uva M., Storey R., Huber K. et al. On behalf of ESC Working Group on Cardiovascular Surgery and ESC Working Group on
Thrombosis. Expert position paper on management of antiplatelet
therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J. 2014; 35 (23): 1510–4. - Price M., Walder J., Baker B. et al. Recovery of platelet function
after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease. The
Recovery Trial. JACC. 2012; 59 (25): 2338–43. - Halvorsen S., Storey R., Rocca B. et al. Management of antithrombotic therapy aft er bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur
Heart J. 2017; 38 (19): 1455–62. - Vassalotti J., Centor R., Turner B. et al. Practical approach to detection and management of chronic kidney disease for the primary
care clinician. Am J Med. 2016; 129 (2): 153–62. e7. DOI: 10.1016/j.
amjmed.2015.08.025. - Carrero J., Varenhorst C., Jensevik K. et al. Long-term versus shortterm dual antiplatelet therapy was similarly associated with a lower
risk of death, stroke, or infarction in patients with acute coronary
syndrome regardless of underlying kidney disease. Kidney Int.
2017; 91 (1): 216–26. - Wiwiott S., Antman E., Winters K. et al. Randomized comparison
of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12
antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO) TIMI 26 Trial. Circulation. 2005; 111
(25): 3366–73. - Wiwiott D., Trenk D., Frelinger L. et al. PRINCIPLE-TIMI 44 Investigators. Circulation. 2007; 118 (25): 2923–32.
- Wiwiott S., Braunwald E., McCabe C. et al. TRITON-TIMI 38
Investigators. Prasugrel versus clopidogrel in patients with acute
coronary syndromes. N Engl J Med. 2007; 357 (20): 2001–15. - Cannon C., Husted S., Harrington R. et al. For the DISPERSE-2
Investigators. Safety, tolerability, and initial efficacy of AZD6140,
the first reversible oral adenosine receptor antagonist, compared
with clopidogrel, patients with non ST-segment elevation acute
coronary syndrome. Primary results of the DISPERSE-2 Trial.
JACC. 2007; 50 (19): 1844–50. - Storey R., Becker R., Harrington R. et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J.
2011; 32 (23): 2945–53. - Campbell K., Cohn J., Fischman D. et al. Management of clopidogrel hypersensitivity without drug interruption. Am J Cardiol. 2011; 107 (6): 812–6.
- Koln P., Windecker S., Alfonso F. et al. ESC/EACTS Guidelines
on myocardial revascularization. Eur Heart J. 2014; 35: 2541–619. - O’Gara P., Kushner F., Ascheim D. et al. FССА/AHA Guideline for
the management of ST-elevation myocardial infarction. A report
of the American College of Cardiology Foundation/American
Heart Association Task Force on practice guidelines. JACC. 2013;
61 (4): 78–140. - Levine G., Bates E., Bittl J. et al. 2016 ACC/AHA Guideline focused
update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation. 2016; 134 (10): e123–55. - Cuisset T., Deharo P., Quilici J. et al. Benefit of switching dual antiplatelet therapy aft er acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017 [Epub ahead of print]. DOI: 10.1093/
eurheartj/ehx175. - Aradi D., Komosci A., Price M. et al. On behalf of tailored antiplatelet treatment study collaboration. Efficacy and safety of intensified
antiplatelet therapy on basis of platelet reactivity testing in patients
after percutaneous coronary interventions: systematic review and
meta-analysis. Int J Cardiol. 2013; 167 (5): 2140–8.
Ключевые слова
агрегация тромбоцитов, клопидогрел, тикагрелор, прасугрел
Опубликован
2017-11-06
Полный текст
